Select Cognition Coverage and Published Editorials
Zervimesine in Alzheimer’s: Cognition Therapeutics and FDA Discuss Phase 2
Clinical Trial Vanguard
By Jon Napitupulu
July 11, 2025
Cognition soars 35% after positive FDA meeting on Alzheimer’s asset zervimesine
Seeking Alpha
By Jonathan Block
July 10, 2025
Cognition Therapeutics Wraps Up FDA Review, Moves Closer to Phase 3 Alzheimer’s Trial
Prism Marketview
By Alex Corbit
July 10, 2025
Armed With Donation From Trial Participant’s Family, Cognition (Nasdaq: CGTX) Initiates Expanded Access Program For Experimental DLB Drug
Benzinga
By Meg Flippin
June 11, 2025
Podcast: How are Biomarkers Shaping Alzheimer’s Disease, and What’s Next?
Touch Neurology
June 4, 2025
With Nicky Cartridge
Cognition Therapeutics Phase 2 Trials Of Zervimesine Show Promise In Treating Dry AMD, Alzheimer’s Disease And Dementia With Lewy Bodies
Benzinga
By Meg Flippin
May 22, 2025
Connect with us on Social Media

